Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
See Latest ArticlesPrognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma
Cancer, 10/26/09
Lughezzani G et al. – The findings of the current study indicate that lymph node stage should be considered in prognostic models. The TNM staging of MRCC patients also should rely on the stage of locoregional lymph nodes, because the 3-year cancer-specific mortality rates of lymph node-negative and lymph node-positive MRCC patients differ by as much as 20%.
Methods- 1153 patients treated with cytoreductive nephrectomy for MRCC, with (negative lymph nodes [N0] vs positive lymph nodes [N1-2]) or without (unknown lymph node stage [Nx]) lymphadenectomy
- Of 797 patients treated with lymphadenectomy, 42.9% found to have lymph node metastases
- Kaplan-Meier plots and univariate and multivariate Cox regression analyses tested statistical significance and independent predictor status of lymph node stage, Fuhrman grade, tumor size, year of surgery, race, sex, and age in patients who underwent lymphadenectomy at time of cytoreductive nephrectomy
- At 3 years after cytoreductive nephrectomy, the cancer-specific mortality-free rates of N1-2 versus N0 versus Nx patients were 14.4% versus 34.7% versus 34.0%, respectively
- Lymph node stage represented most informative variable and achieved independent predictor status in multivariate models
- Consideration of lymph node stage added 3.2% accuracy to other predictors of cancer-specific mortality
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia
Clinical Journal of the American Society of Nephrology, 11/05/09
Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Annals of Oncology, 10/29/09
Article Search
Sponsor